An investigational cancer vaccine may help people with acute myeloid leukemia (AML) live longer, according to promising results from a phase 3 clinical trial.
Galinpepimut-S (GPS) is an experimental vaccine developed by SELLAS Life Sciences. Results shared from the phase 3 REGAL clinical trial showed that the vaccine reduced the risk of death for people with AML by 41% compared to other available treatments.
Although the vaccine is not yet approved by the U.S. Food and Drug Administration (FDA), the findings offer hope for patients with AML who have limited treatment options.
What did the REGAL clinical trial find?
The REGAL clinical trial included 126 patients with AML. The participants had been treated for AML twice and could not undergo a stem cell transplant.
Researchers compared Galinpepimut-S with other available treatments to determine whether the vaccine could improve survival. Half received the investigational Galinpepimut-S vaccine. The other half received the best available treatment.
The Washington Post reported that study results showed:
41% lower risk of death: Patients receiving Galinpepimut-S had a 41% lower risk of death during the study compared to those receiving other available treatments.
Longer survival: Median overall survival was 24 months for patients receiving GPS, compared to 14.7 months for those receiving other treatments.
Manageable side effects: Most treatment-related side effects were mild to moderate. Reactions at the injection site were the most common.
Median overall survival refers to the amount of time at which half of the patients in a group are still alive. It does not predict how long an individual patient will live.
These findings are encouraging because AML can be difficult to treat, particularly when the disease returns after previous treatment.
How does the AML vaccine work?
Even when a person reaches remission, some leukemia cells may remain undetected. These cells can eventually cause the cancer to return. Galinpepimut-S is an “off-the-shelf” vaccine. This means that it does not need to be developed separately for each patient.
The vaccine uses synthetic peptides. Peptides are chains of amino acids that can affect the body. The vaccine targets Wilms tumor 1 (WT1), a protein found in 95% of people with AML. This triggers a response that helps the immune system recognize and attack leukemia cells that may remain in the body after previous treatments. Researchers are hopeful that the vaccine can help patients stay in remission longer.
In a press release about the clinical trial, the REGAL steering committee shared, “The landmark data from the Phase 3 REGAL trial demonstrate a statistically significant and clinically meaningful overall survival advantage for the Galinpepimut-S immunotherapeutic cancer vaccine in this underserved population. By training the immune system to target residual leukemia cells, Galinpepimut-S addresses a critical unmet need and has the potential to redefine the treatment paradigm in AML maintenance therapy.”
What this means for people with AML
Although medications can help patients achieve remission for AML, the disease can return. For some patients, a stem cell transplant can lead to long-term remission. However, not everyone is eligible for a transplant due to age, overall health, or other medical conditions. This creates a need for additional treatments that can prolong remission.
The vaccine could eventually provide another option for patients who have already undergone multiple treatments and cannot receive a transplant.
What happens next?
The results announced are preliminary, and researchers are continuing to evaluate additional findings. Research is ongoing to determine whether GPS could benefit patients at other stages of the disease.
Sellas plans to meet with the FDA to discuss the approval process and prepare a submission during the first half of 2027. If approved, Galinpepimut-S could become an important new treatment option for certain patients with AML.
What should patients know?
The results of this study represent an encouraging development in AML research, particularly for patients who experience a relapse and have limited treatment options. It is important to speak with your healthcare team about whether a clinical trial may be appropriate for you. They will help you make a decision based on your medical history and current overall health.
Stay informed about advances in AML treatment.
Create a free HealthTree account to explore clinical trials, learn about new research, and connect with resources that can help you make informed decisions about your care.
Sources:


